Fluicell AB (SE:FLUI)
:FLUI
Top Page
Fluicell AB
(FLUI)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr14.50
▲(45.00% Upside)
Action:ReiteratedDate:02/23/26
The score is held back primarily by weak financial performance—ongoing losses and significant cash burn—despite a strong TTM revenue rebound and a zero-debt balance sheet. Technical indicators are moderately supportive in the near term, while valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Low leverage / Zero debt
A zero-debt capital structure materially reduces refinancing and interest-rate risk, giving management flexibility to time funding and investment. Over 2–6 months this lowers bankruptcy risk and supports strategic options (R&D, partnerships) without immediate leverage constraints.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow implies reliance on external funding and dilution risk. Over the next several quarters, continued cash burn can constrain R&D and go-to-market investments and force financing at unfavorable terms, limiting strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / Zero debt
A zero-debt capital structure materially reduces refinancing and interest-rate risk, giving management flexibility to time funding and investment. Over 2–6 months this lowers bankruptcy risk and supports strategic options (R&D, partnerships) without immediate leverage constraints.
Read all positive factors
Fluicell AB (FLUI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr18.68M
Dividend YieldN/A
Average Volume (3M)16.23K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,373,703
10 Day Avg. Volume8,193
30 Day Avg. Volume16,225
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr68.60M
Fluicell AB Business Overview & Revenue Model
Company Description
Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery...
How the Company Makes Money
null...
Fluicell AB Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
60
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.00M | 1.86M | 3.34M | 3.25M | 2.60M |
| Gross Profit | -8.69M | 3.76M | 1.74M | 2.59M | 1.89M |
| EBITDA | -8.31M | -14.99M | -25.91M | -20.89M | -21.08M |
| Net Income | -8.33M | -15.51M | -26.55M | -21.49M | -21.72M |
Balance Sheet | |||||
| Total Assets | 18.48M | 25.51M | 9.34M | 31.77M | 26.98M |
| Cash, Cash Equivalents and Short-Term Investments | 2.26M | 15.92M | 2.76M | 24.46M | 20.69M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.57M | 6.27M | 8.91M | 8.32M | 7.87M |
| Stockholders Equity | 10.90M | 19.23M | 425.00K | 23.45M | 19.11M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -15.67M | -27.23M | -22.18M | -19.41M |
| Operating Cash Flow | -4.95M | -15.67M | -27.23M | -21.04M | -18.64M |
| Investing Cash Flow | -8.67M | -3.49M | 0.00 | -1.14M | -772.00K |
| Financing Cash Flow | 0.00 | 32.32M | 5.53M | 25.94M | 21.31M |
Fluicell AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:FLUI
Fluicell AB
13.60
1.18
9.50%
DE:9F1
Diagonal Bio AB
0.10
0.00
0.00%
DE:65G
NextCell Pharma AB
0.11
0.01
12.00%
DE:COJ0
CombiGene AB
0.15
-0.02
-10.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.